 | |
| Scheduled U.S. IPOs - Week of 02/03/2014 | |
| Argos Therapeutics (ARGS) - Durham, NC Deal Size: $60 mil Price Range: $13.00 - $15.00 Shares Filed: 4,250,000 Lead Underwriter: Piper Jaffray Developing immunotherapies for the treatment of cancer and HIV. | |
| Auspex Pharmaceuticals (ASPX) - San Diego, CA Deal Size: $61 mil Price Range: $10.00 - $12.00 Shares Filed: 5,500,000 Lead Underwriter: Stifel Clinical-stage biotech developing treatments for orphan diseases. | |
| Biocept (BIOC) - San Diego, CA Deal Size: $20 mil Price Range: $10.00 - $12.00 Shares Filed: 1,818,181 Lead Underwriter: Aegis Capital Corp. Develops and markets cancer diagnostic tests. | |
| Continental Building Products (CBPX) - Reston, VA Deal Size: $225 mil Price Range: $16.00 - $18.00 Shares Filed: 13,236,000 Lead Underwriter: Citi Manufactures and sells drywall in the eastern US and Canada. | |
| Egalet (EGLT) - Malvern, PA Deal Size: $42 mil Price Range: $11.00 - $13.00 Shares Filed: 3,500,000 Lead Underwriter: Stifel Developing abuse-deterrent oral products for the treatment of pain. | |
| Eleven Biotherapeutics (EBIO) - Cambridge, MA Deal Size: $60 mil Price Range: $13.00 - $15.00 Shares Filed: 4,300,000 Lead Underwriter: Citi Clinical-stage biotech developing protein therapeutics to treat eye diseases. | |
| Genocea Biosciences (GNCA) - Cambridge, MA Deal Size: $72 mil Price Range: $12.00 - $14.00 Shares Filed: 5,500,000 Lead Underwriter: Citi Develops novel vaccines for infectious diseases through T cell immune responses. | |
| GeoPark (GPRK) - Santiago, Chile Deal Size: $180 mil Price Range: $8.00 - $10.00 Shares Filed: 20,000,000 Lead Underwriter: J.P. Morgan Oil and natural gas E&P operating in Chile, Colombia and Brazil. | |
| Ladder Capital (LADR) - New York, NY Deal Size: $225 mil Price Range: $16.00 - $18.00 Shares Filed: 13,250,000 Lead Underwriter: Deutsche Bank Commercial real estate mortgage origination and finance company. | |
| NephroGenex (NRX) - Research Triangle Park, NC Deal Size: $40 mil Price Range: $12.00 - $14.00 Shares Filed: 3,100,000 Lead Underwriter: Aegis Capital Corp. Clinical-stage biotech developing treatments for kidney disease. | |
| Revance Therapeutics (RVNC) - Newark, CA Deal Size: $75 mil Price Range: $14.00 - $16.00 Shares Filed: 5,000,000 Lead Underwriter: Cowen & Company Clinical-stage biotech developing enhanced formulations of botulinum toxin (Botox). | |
| uniQure (QURE) - Amsterdam, Netherlands Deal Size: $64 mil Price Range: $13.00 - $15.00 Shares Filed: 4,600,000 Lead Underwriter: Jefferies & Co. Develops gene therapies for the treatment of orphan diseases. | |
| IPO Commentary |
| Dicerna Pharmaceuticals, which is developing RNAi therapeutics for the treatment of rare liver disease and cancer, kicked off a... more |
| Last year saw the most biotech IPO activity in over a decade, both in number of deals (37) and proceeds ($2.7B). Yet when the Q4 experienced a 50% decline in the number of these IPOs over the Q3, and especially when 6 deal... more |
| IPO Performance |
| The FTSE Renaissance IPO Index has returned 3.7% so far this year, compared to-2.9% for the S&P 500. |
 |
| IPO Activity |
| There have been 17 IPOs priced so far this year, a +42% change from last year. |
 |
| About Renaissance Capital Renaissance Capital is a global IPO investment advisor providing institutional research, investment management and indexing services. The Firm's IPO Intelligence research services provide pre-IPO fundamental analysis and global IPO market analytics to the top institutional buyers of IPOs. Renaissance Capital manages portfolios of unseasoned equities through the Global IPO Fund (symbol: IPOSX), the Renaissance IPO ETF (symbol: IPO) and separately managed institutional accounts. The Firm maintains the FTSE Renaissance Global IPO Index Series (symbols: IPOS, IPOSG), which serve as benchmarks of IPO performance and are used as the basis for investment products. For more information, visit www.renaissancecapital.com. |
No comments:
Post a Comment